Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection

Journal of Immunology

Volumn 190, Issue 3, 2013, Pages 1135-1147

  Elias, Sean C ^a   Collins, Katharine A ^a   Halstead, Fenella D ^a   Choudhary, Prateek ^a   Bliss, Carly M ^a   Ewer, Katie J ^b   Sheehy, Susanne H ^a   Duncan, Christopher J A ^a,b   Biswas, Sumi ^a   Hill, Adrian V S ^a   Draper, Simon J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APICAL MEMBRANE ANTIGEN 1; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1;

ALLELE; ANTIGENIC VARIATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALARIA; NORMAL HUMAN; PARASITE CONTROL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VOLUNTEER;

ADENOVIRIDAE; ADULT; ALLELES; ANTIBODIES, PROTOZOAN; ANTIGENIC VARIATION; ANTIGENS, PROTOZOAN; DEFECTIVE VIRUSES; EPITOPES; ERYTHROCYTES; GENETIC VECTORS; HLA ANTIGENS; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MALARIA VACCINES; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; MEROZOITE SURFACE PROTEIN 1; PEPTIDE FRAGMENTS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; T-LYMPHOCYTES; VACCINATION; VACCINES, SUBUNIT; VACCINIA VIRUS;

EID: 84872741492     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201455     Document Type: Article

References (54)

1. Hill, A. V. 2011. Vaccines against malaria. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366: 2806-2814.
2. Goodman, A. L., and S. J. Draper. 2010. Blood-stage malaria vaccines: Recent progress and future challenges. Ann. Trop. Med. Parasitol. 104: 189-211.
3. Holder, A. A. 2009. The carboxy-terminus of merozoite surface protein 1: Structure, specific antibodies and immunity to malaria. Parasitology 136: 1445-1456.
4. Remarque, E. J., B. W. Faber, C. H. Kocken, and A. W. Thomas. 2008. Apical membrane antigen 1: A malaria vaccine candidate in review. Trends Parasitol. 24: 74-84.
5. Riley, E. M., S. J. Allen, J. G. Wheeler, M. J. Blackman, S. Bennett, B. Takacs, H. J. Schonfeld, A. A. Holder, and B. M. Greenwood. 1992. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol. 14: 321-337.
6. Polley, S. D., T. Mwangi, C. H. Kocken, A. W. Thomas, S. Dutta, D. E. Lanar, E. Remarque, A. Ross, T. N. Williams, G. Mwambingu, et al. 2004. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23: 718-728. (Pubitemid 39473204)
7. Fowkes, F. J., J. S. Richards, J. A. Simpson, and J. G. Beeson. 2010. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med. 7: E1000218.
8. Draper, S. J., A. C. Moore, A. L. Goodman, C. A. Long, A. A. Holder, S. C. Gilbert, F. Hill, and A. V. Hill. 2008. Effective induction of high-titer antibodies by viral vector vaccines. Nat. Med. 14: 819-821.
9. Xu, H., A. N. Hodder, H. Yan, P. E. Crewther, R. F. Anders, and M. F. Good. 2000. CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. J. Immunol. 165: 389-396. (Pubitemid 30429531)
10. Biswas, S., A. J. Spencer, E. K. Forbes, S. C. Gilbert, A. A. Holder, A. V. Hill, and S. J. Draper. 2012. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: Mechanisms of vaccineinduced blood-stage protection. J. Immunol. 188: 5041-5053.
11. Darko, C. A., E. Angov, W. E. Collins, E. S. Bergmann-Leitner, A. S. Girouard, S. L. Hitt, J. S. McBride, C. L. Diggs, A. A. Holder, C. A. Long, et al. 2005. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect. Immun. 73: 287-297. (Pubitemid 40041120)
12. Lyon, J. A., E. Angov, M. P. Fay, J. S. Sullivan, A. S. Girourd, S. J. Robinson, E. S. Bergmann-Leitner, E. H. Duncan, C. A. Darko, W. E. Collins, et al. 2008. Protection induced by Plasmodium falciparum MSP142 is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS ONE 3: E2830.
13. Mahdi Abdel Hamid, M., E. J. Remarque, L. M. van Duivenvoorde, N. van der Werff, V. Walraven, B. W. Faber, C. H. Kocken, and A. W. Thomas. 2011. Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques. PLoS ONE 6: E20547.
14. Dutta, S., J. S. Sullivan, K. K. Grady, J. D. Haynes, J. Komisar, A. H. Batchelor, L. Soisson, C. L. Diggs, D. G. Heppner, D. E. Lanar, et al. 2009. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS ONE 4: E8138.
15. Good, M. F., and C. Engwerda. 2011. Defying malaria: Arming T cells to halt malaria. Nat. Med. 17: 49-51.
16. Good, M. F., H. Xu, M. Wykes, and C. R. Engwerda. 2005. Development and regulation of cell-mediated immune responses to the blood stages of malaria: Implications for vaccine research. Annu. Rev. Immunol. 23: 69-99. (Pubitemid 40563165)
17. Bouharoun-Tayoun, H., P. Attanath, A. Sabchareon, T. Chongsuphajaisiddhi, and P. Druilhe. 1990. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 172: 1633-1641.
18. Joos, C., L. Marrama, H. E. Polson, S. Corre, A. M. Diatta, B. Diouf, J. F. Trape, A. Tall, S. Longacre, and R. Perraut. 2010. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS ONE 5: E9871.
19. Belnoue, E., T. Voza, F. T. Costa, A. C. Gruner, M. Mauduit, D. S. Rosa, N. Depinay, M. Kayibanda, A. M. Vigário, D. Mazier, et al. 2008. Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage. J. Immunol. 181: 8552-8558.
20. Draper, S. J., A. L. Goodman, S. Biswas, E. K. Forbes, A. C. Moore, S. C. Gilbert, and A. V. Hill. 2009. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody-and T cell-mediated multistage protection against malaria. Cell Host Microbe 5: 95-105.
21. Imai, T., J. Shen, B. Chou, X. Duan, L. Tu, K. Tetsutani, C. Moriya, H. Ishida, S. Hamano, C. Shimokawa, et al. 2010. Involvement of CD8+ T cells in protective immunity against murine blood-stage infection with Plasmodium yoelii 17XL strain. Eur. J. Immunol. 40: 1053-1061.
22. Hill, A. V. S., A. Reyes-Sandoval, G. O'Hara, K. Ewer, A. M. Lawrie, A. L. Goodman, A. Nicosia, A. Folgori, S. Colloca, R. Cortese, et al. 2010. Primeboost vectored malaria vaccines: Progress and prospects. Hum. Vaccin. 6: 78-83.
23. Draper, S. J., and J. L. Heeney. 2010. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8: 62-73.
24. Sheehy, S. H., C. J. Duncan, S. C. Elias, K. A. Collins, K. J. Ewer, A. J. Spencer, A. R. Williams, F. D. Halstead, S. E. Moretz, K. Miura, et al. 2011. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol. Ther. 19: 2269-2276.
25. Sheehy, S. H., C. J. Duncan, S. C. Elias, S. Biswas, K. A. Collins, G. A. O'Hara, F. D. Halstead, K. J. Ewer, T. Mahungu, A. J. Spencer, et al. 2012. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 7: E31208.
26. Sheehy, S. H., C. J. Duncan, S. C. Elias, P. Choudhary, S. Biswas, F. D. Halstead, K. A. Collins, N. J. Edwards, A. D. Douglas, N. A. Anagnostou, et al. 2012. ChAd63-MVA-vectored glood-stage malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 20: 2355-2368.
27. Thera, M. A., O. K. Doumbo, D. Coulibaly, M. B. Laurens, A. Ouattara, A. K. Kone, A. B. Guindo, K. Traore, I. Traore, B. Kouriba, et al. 2011. A field trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 365: 1004-1013.
28. Ellis, R. D., L. B. Martin, D. Shaffer, C. A. Long, K. Miura, M. P. Fay, D. L. Narum, D. Zhu, G. E. Mullen, S. Mahanty, et al. 2010. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS ONE 5: E8787.
29. Duncan, C. J., S. H. Sheehy, K. J. Ewer, A. D. Douglas, K. A. Collins, F. D. Halstead, S. C. Elias, P. J. Lillie, K. Rausch, J. Aebig, et al. 2011. Impact on malaria parasite multiplication rates in infected volunteers of the protein-inadjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS ONE 6: E22271.
30. Kusi, K. A., B. W. Faber, A. W. Thomas, and E. J. Remarque. 2009. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS ONE 4: E8110.
31. Remarque, E. J., B. W. Faber, C. H. Kocken, and A. W. Thomas. 2008. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect. Immun. 76: 2660-2670.
32. Biswas, S., M. D. Dicks, C. A. Long, E. J. Remarque, L. Siani, S. Colloca, M. G. Cottingham, A. A. Holder, S. C. Gilbert, A. V. Hill, and S. J. Draper. 2011. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS ONE 6: E20977.
33. Draper, S. J., S. Biswas, A. J. Spencer, E. J. Remarque, S. Capone, M. Naddeo, M. D. J. Dicks, B. W. Faber, S. C. de Cassan, A. Folgori, et al. 2010. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J. Immunol. 185: 7583-7595.
34. Goodman, A. L., C. Epp, D. Moss, A. A. Holder, J. M. Wilson, G. P. Gao, C. A. Long, E. J. Remarque, A. W. Thomas, V. Ammendola, et al. 2010. New candidate vaccines against blood-stage Plasmodium falciparum malaria: Primeboost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect. Immun. 78: 4601-4612.
35. Tanabe, K., M. Mackay, M. Goman, and J. G. Scaife. 1987. Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 195: 273-287. (Pubitemid 17106691)
36. Gilbert, S. C., M. Plebanski, S. Gupta, J. Morris, M. Cox, M. Aidoo, D. Kwiatkowski, B. M. Greenwood, H. C. Whittle, and A. V. Hill. 1998. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 279: 1173-1177. (Pubitemid 28164361)
37. Plebanski, M., E. A. Lee, C. M. Hannan, K. L. Flanagan, S. C. Gilbert, M. B. Gravenor, and A. V. Hill. 1999. Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nat. Med. 5: 565-571. (Pubitemid 29220217)
38. Lee, E. A., K. L. Flanagan, G. Minigo, W. H. Reece, R. Bailey, M. Pinder, A. V. Hill, and M. Plebanski. 2006. Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming. Eur. J. Immunol. 36: 1168-1178.
39. Lee, E. A., K. L. Flanagan, K. Odhiambo, W. H. Reece, C. Potter, R. Bailey, K. Marsh, M. Pinder, A. V. Hill, and M. Plebanski. 2001. Identification of frequently recognized dimorphic T-cell epitopes in plasmodium falciparum merozoite surface protein-1 in West and East Africans: Lack of correlation of immune recognition and allelic prevalence. Am. J. Trop. Med. Hyg. 64: 194-203. (Pubitemid 32565850)
40. Klenerman, P., U. C. Meier, R. E. Phillips, and A. J. McMichael. 1995. The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. Eur. J. Immunol. 25: 1927-1931.
41. Kaneko, T., T. Moriyama, K. Udaka, K. Hiroishi, H. Kita, H. Okamoto, H. Yagita, K. Okumura, and M. Imawari. 1997. Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope. Eur. J. Immunol. 27: 1782-1787. (Pubitemid 27302864)
42. Quin, S. J., E. M. Seixas, C. A. Cross, M. Berg, V. Lindo, B. Stockinger, and J. Langhorne. 2001. Low CD4+ T cell responses to the C-terminal region of the malaria merozoite surface protein-1 may be attributed to processing within distinct MHC class II pathways. Eur. J. Immunol. 31: 72-81.
43. Stanisic, D. I., L. B. Martin, X. Q. Liu, D. Jackson, J. Cooper, and M. F. Good. 2003. Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface protein 1 of Plasmodium yoelii: Rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination. Infect. Immun. 71: 5700-5713. (Pubitemid 37205623)
44. Sauerwein, R. W., M. Roestenberg, and V. S. Moorthy. 2011. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat. Rev. Immunol. 11: 57-64.
45. Hensmann, M., C. Li, C. Moss, V. Lindo, F. Greer, C. Watts, S. A. Ogun, A. A. Holder, and J. Langhorne. 2004. Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response. Eur. J. Immunol. 34: 639-648. (Pubitemid 39255911)
46. Huaman, M. C., L. B. Martin, E. Malkin, D. L. Narum, L. H. Miller, S. Mahanty, and C. A. Long. 2008. Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. J. Immunol. 180: 1451-1461.
47. Egan, A., M. Waterfall, M. Pinder, A. Holder, and E. Riley. 1997. Characterization of human T-and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: Evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds. Infect. Immun. 65: 3024-3031. (Pubitemid 27342373)
48. Crisanti, A., K. Fruh, H. M. Muller, and H. Bujard. 1990. The T cell reactivity against the major merozoite protein of Plasmodium falciparum. Immunol. Lett. 25: 143-148. (Pubitemid 20260860)
49. Udhayakumar, V., D. Anyona, S. Kariuki, Y. P. Shi, P. B. Bloland, O. H. Branch, W. Weiss, B. L. Nahlen, D. C. Kaslow, and A. A. Lal. 1995. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J. Immunol. 154: 6022-6030.
50. Allsopp, C. E., R. M. Harding, C. Taylor, M. Bunce, D. Kwiatkowski, N. Anstey, D. Brewster, A. J. McMichael, B. M. Greenwood, and A. V. Hill. 1992. Interethnic genetic differentiation in Africa: HLA class I antigens in The Gambia. Am. J. Hum. Genet. 50: 411-421.
51. Luo, M., J. Embree, S. Ramdahin, J. Ndinya-Achola, S. Njenga, J. B. Bwayo, S. Pan, X. Mao, M. Cheang, T. Stuart, et al. 2002. HLA-A and HLA-B in Kenya, Africa: Allele frequencies and identification of HLA-B*1567 and HLA-B*4426. Tissue Antigens 59: 370-380.
52. Conway, D. J., B. M. Greenwood, and J. S. McBride. 1992. Longitudinal study of Plasmodium falciparum polymorphic antigens in a malaria-endemic population. Infect. Immun. 60: 1122-1127.
53. Takala, S. L., D. Coulibaly, M. A. Thera, A. Dicko, D. L. Smith, A. B. Guindo, A. K. Kone, K. Traore, A. Ouattara, A. A. Djimde, et al. 2007. Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med. 4: E93.
54. Babiker, H. A., A. M. Creasey, B. Fenton, R. A. Bayoumi, D. E. Arnot, and D. Walliker. 1991. Genetic diversity of Plasmodium falciparum in a village in eastern Sudan, 1: Diversity of enzymes, 2D-PAGE proteins and antigens. Trans. R. Soc. Trop. Med. Hyg. 85: 572-577.